241 related articles for article (PubMed ID: 18754868)
1. Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer.
Ohara S; Oue N; Matsubara A; Mita K; Hasegawa Y; Hayashi T; Usui T; Amatya VJ; Takeshima Y; Kuniyasu H; Yasui W
Cancer Sci; 2008 Aug; 99(8):1570-7. PubMed ID: 18754868
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.
Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W
Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
4. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
6. Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy.
Lin HC; Liu CC; Kang WY; Yu CC; Wu TT; Wang JS; Wu WJ; Huang CH; Wu MT; Huang SP
Urol Int; 2009; 83(4):463-70. PubMed ID: 19996656
[TBL] [Abstract][Full Text] [Related]
7. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.
Moul JW; Maygarden SJ; Ware JL; Mohler JL; Maher PD; Schenkman NS; Ho CK
J Urol; 1996 Mar; 155(3):982-5. PubMed ID: 8583622
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
11. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
[TBL] [Abstract][Full Text] [Related]
12. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
14. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
16. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
17. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma.
Oue N; Mitani Y; Aung PP; Sakakura C; Takeshima Y; Kaneko M; Noguchi T; Nakayama H; Yasui W
J Pathol; 2005 Oct; 207(2):185-98. PubMed ID: 16086444
[TBL] [Abstract][Full Text] [Related]
18. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Ting WC; Chen LM; Huang LC; Liu CC; Chen CW; Hsieh CJ; Yang WH; Chang TY; Lee HZ; Bao BY
Ann Surg Oncol; 2010 Jan; 17(1):312-22. PubMed ID: 19777185
[TBL] [Abstract][Full Text] [Related]
19. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
[TBL] [Abstract][Full Text] [Related]
20. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy.
Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O
Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
